Sanara MedTech Q1 revenue $15.5M, up 99% YoY; net loss narrows to $1.2M

Sanara MedTech Inc.

2024-Q1 EPS reported -$0.14 revenue$15,521,917

Net revenues $15.5M (99% YoY increase); net loss $1.2M vs $3.2M prior year.
Gross margin 86% vs 90% prior year due to lower margins on Scendia products.
SG&A $13.0M (up $3.6M) driven by higher sales commissions and sales force expansion.
Scendia sales flat at $3.0M; ALLOCYTE supply issues persist, expected resolution H2 2023.
Received 510(k) clearance for BIASURGE Advanced Surgical Solution; preparing launch late 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sanara MedTech Inc. reported the quarter ended March 31, 2023 results: revenue $15.5 million, net income net loss of $1.2 million.

Period: the quarter ended March 31, 2023
Revenue: $15.5 million
Net income: net loss of $1.2 million
Result: reported results

Exact text from the filing

clearance for BIASURGETM. First Quarter 2023 Consolidated Financial Results (Unaudited) ● Net Revenues. For the three months ended March 31, 2023, we generated net revenues of $15.5 million compared to net revenues of $7.8 million for the three months ended March 31, 2022, a 99% increase from the prior year period. Our net revenues for the three months ended March

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sanara MedTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-017398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.